# Molecular Imaging

> **NIH NIH P30** · WAYNE STATE UNIVERSITY · 2022 · $39,215

## Abstract

MOLECULAR IMAGING (MI) – ABSTRACT
The overall goal of the Molecular Imaging (MI) Program at KCI is to develop new imaging technologies through
pre-clinical, early clinical and national studies to better understand tumor physiology, aid in the assessment of
novel therapeutic approaches and make new imaging methods available to improve routine clinical care. This
highly integrated Program includes 24 members from 7 departments and 4 schools at Wayne State University
and $3,541,404 in peer reviewed cancer-related funding, of which $772,287 is from the NCI. The MI Program
is led by Dr. Juri Gelovani as Program Leader and Dr. Nerissa Viola as a Program Co-Leader. The MI Program
is built on close collaborations among the imaging scientists, biomedical engineers, chemists, biologists, clinical
oncologists, radiologists, and nuclear medicine physicians. Members with complementary expertise work with
colleagues from other KCI Programs to apply their expertise in molecular imaging to answer important biological
and clinical questions. Together investigators conduct research using our integrated small animal imaging core
facility with optical, 7T MR, microPET/CT, microSPECT/CT, and a recently-installed large animal (clinical)
PET/CT scanner, the developing Cyclotron-Radiochemistry Core and other Shared Resources at KCI. Molecular
imaging is also being used to complement genetic and epigenetic analyses of tumor specimens. While genetic
and epigenetic analyses can investigate thousands of genes simultaneously, imaging allows investigators to
study the magnitude and heterogeneity of the gene product expression-activity non-invasively and to obtain such
repeated measurements over the course of tumor progression and response to treatment. Furthermore,
functional measurements obtained with molecular imaging can assist in determining if a particular pathway is
active and if it is important in tumor physiology, something that simple measurements of gene expression or
protein level in vitro or in situ may not be able to demonstrate. Bioengineering experts in the MI Program are
developing novel instruments and methods for structural, functional, and molecular imaging of cancer, including
novel MRI sequences, instruments for hyperpolarization of agents and hpMR spectroscopic imaging, ultrasound
tomography and photoacoustic imaging. The ultimate goal of the MI Program is to translate the results of pre-
clinical research into the clinic. Several imaging agents, methods, and instruments developed "in house” are now
progressing to early phase clinical trials. All members of the MI Program actively collaborate with members of
the TBM, MT, and PSDR Programs at KCI. Of the 333 manuscripts published between December 2015 and
November 2019, 39% and 30% were intra- and inter-programmatic, respectively, and 66% were multi-
institutional collaborations.

## Key facts

- **NIH application ID:** 10348663
- **Project number:** 5P30CA022453-40
- **Recipient organization:** WAYNE STATE UNIVERSITY
- **Principal Investigator:** Juri George Gelovani
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $39,215
- **Award type:** 5
- **Project period:** 1997-08-08 → 2025-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10348663

## Citation

> US National Institutes of Health, RePORTER application 10348663, Molecular Imaging (5P30CA022453-40). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10348663. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*